Form 4 for ZYME Zymeworks Inc.
Accepted 2024-01-08 00:00:00 ET · period of report 2024-01-05 · accession 0000950170-24-003076 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-08 | 2024-01-05+ | ZYME | Moore Paul Andrew | CSO | S - Sale+OE | $10.79 | -9,799 | 9,706 | -50% | -$105.7K |
| D | 2024-01-08 | 2024-01-05 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | +17.2K | 17.2K | New | $0 |
| DM | 2024-01-08 | 2024-01-05 | ZYME | Moore Paul Andrew | CSO | A - Grant | $0.00 | +150.0K | 90.0K | New | $0 |
| D | 2024-01-08 | 2024-01-05 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | -17.2K | 34.3K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-08 | S | D | 2,339 | $11.22 | 7,367 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-01-05 | M | A | 17,166 | $0.00 | 17,166 | D | — | — | (F1) Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. |
| 3 | Common | Common Stock | 2024-01-05 | S | D | 7,460 | $10.65 | 9,706 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Restricted Stock Unit | 2024-01-05 | A | A | 60,000 | $0.00 | 60,000 | D | — · — to — | 60,000 Common Stock | (F5) Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. (F8) The RSUs vest in three equal annual installments beginning on January 5, 2025. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-01-05 | A | A | 90,000 | $0.00 | 90,000 | D | $10.56 · — to 2034-01-04 | 90,000 Common Stock | (F7) Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. |
| 6 | Derivative | Restricted Stock Unit | 2024-01-05 | M | D | 17,166 | $0.00 | 34,334 | D | — · — to — | 17,166 Common Stock | (F5) Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. (F6) The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. |